FI114095B - Menetelmä ja diastereomeerisia suoloja, jotka ovat käyttökelpoisia raseemisen 4-[4-[4-(hydroksidifenyylimetyyli)- 1-piperidinyyli]-1-hydroksibutyyli]-alfaalfa-dimetyylibentseenietikkahapon optisessa resoluutiossa - Google Patents
Menetelmä ja diastereomeerisia suoloja, jotka ovat käyttökelpoisia raseemisen 4-[4-[4-(hydroksidifenyylimetyyli)- 1-piperidinyyli]-1-hydroksibutyyli]-alfaalfa-dimetyylibentseenietikkahapon optisessa resoluutiossa Download PDFInfo
- Publication number
- FI114095B FI114095B FI964566A FI964566A FI114095B FI 114095 B FI114095 B FI 114095B FI 964566 A FI964566 A FI 964566A FI 964566 A FI964566 A FI 964566A FI 114095 B FI114095 B FI 114095B
- Authority
- FI
- Finland
- Prior art keywords
- compound
- solution
- diastereomeric
- diastereomeric salt
- acid
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 97
- 230000003287 optical effect Effects 0.000 title claims abstract description 41
- -1 hydroxydiphenylmethyl Chemical group 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 26
- 150000001875 compounds Chemical class 0.000 claims abstract description 51
- 239000003960 organic solvent Substances 0.000 claims description 24
- NTOIKDYVJIWVSU-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-UHFFFAOYSA-N 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 230000007062 hydrolysis Effects 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 230000002452 interceptive effect Effects 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- RWTNPBWLLIMQHL-GDLZYMKVSA-N 2-[4-[(1r)-1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-ium-1-yl]butyl]phenyl]-2-methylpropanoate Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1[C@H](O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-GDLZYMKVSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 abstract description 59
- 239000003795 chemical substances by application Substances 0.000 abstract description 26
- 239000002253 acid Substances 0.000 abstract description 18
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract description 14
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 abstract description 7
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 abstract description 3
- 230000001376 precipitating effect Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 112
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 78
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 76
- 239000013078 crystal Substances 0.000 description 54
- 229960002510 mandelic acid Drugs 0.000 description 49
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 48
- 239000000126 substance Substances 0.000 description 33
- 229910001868 water Inorganic materials 0.000 description 28
- 238000000921 elemental analysis Methods 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 238000002425 crystallisation Methods 0.000 description 21
- 230000008025 crystallization Effects 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 16
- 238000002329 infrared spectrum Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 14
- 229960000351 terfenadine Drugs 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000001914 filtration Methods 0.000 description 12
- JEHUZVBIUCAMRZ-UHFFFAOYSA-N 1,1'-binaphthyl-2,2'-diyl hydrogenphosphate Chemical compound O1P(O)(=O)OC2=CC=C(C=CC=C3)C3=C2C2=C1C=CC1=CC=CC=C21 JEHUZVBIUCAMRZ-UHFFFAOYSA-N 0.000 description 11
- GUGOEEXESWIERI-SSEXGKCCSA-N (1r)-1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol Chemical compound C1=CC(C(C)(C)C)=CC=C1[C@H](O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-SSEXGKCCSA-N 0.000 description 10
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 10
- 238000001953 recrystallisation Methods 0.000 description 10
- 239000012452 mother liquor Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- GUGOEEXESWIERI-PMERELPUSA-N (1s)-1-(4-tert-butylphenyl)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butan-1-ol Chemical compound C1=CC(C(C)(C)C)=CC=C1[C@@H](O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-PMERELPUSA-N 0.000 description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 238000004296 chiral HPLC Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 125000003386 piperidinyl group Chemical group 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 230000005526 G1 to G0 transition Effects 0.000 description 4
- AGSHNVIRVSPYHS-UHFFFAOYSA-N ethanol;4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound CCO.C1CC2(C)C(=O)CC1C2(C)C AGSHNVIRVSPYHS-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- FYUNQERIZAJDPT-ZVGUSBNCSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;ethanol Chemical compound CCO.OC(=O)[C@H](O)[C@@H](O)C(O)=O FYUNQERIZAJDPT-ZVGUSBNCSA-N 0.000 description 3
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 3
- VVCDFKVNYPHNCW-DKWTVANSSA-N C(C)O.C([C@@H](O)CC(=O)O)(=O)O Chemical compound C(C)O.C([C@@H](O)CC(=O)O)(=O)O VVCDFKVNYPHNCW-DKWTVANSSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 3
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- SFLMUHDGSQZDOW-FAOXUISGSA-N coniferin Chemical compound COC1=CC(\C=C\CO)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SFLMUHDGSQZDOW-FAOXUISGSA-N 0.000 description 3
- SFLMUHDGSQZDOW-IBEHDNSVSA-N coniferoside Natural products COC1=CC(C=CCO)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SFLMUHDGSQZDOW-IBEHDNSVSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940116298 l- malic acid Drugs 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 3
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 101150106653 Ren1 gene Proteins 0.000 description 2
- 229920002807 Thiomer Polymers 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 150000001555 benzenes Chemical class 0.000 description 2
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 2
- BKGNRWXKVMPQJE-UHFFFAOYSA-N ethyl 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoate Chemical compound C1=CC(C(C)(C)C(=O)OCC)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 BKGNRWXKVMPQJE-UHFFFAOYSA-N 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- YNXICDMQCQPQEW-UHFFFAOYSA-N 1-naphthyl dihydrogen phosphate Chemical compound C1=CC=C2C(OP(O)(=O)O)=CC=CC2=C1 YNXICDMQCQPQEW-UHFFFAOYSA-N 0.000 description 1
- XVNKNFCMXHXIPO-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid;hydrate Chemical compound O.C1=CC(C)=CC=C1C(=O)C(O)(C(O)=O)C(O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 XVNKNFCMXHXIPO-UHFFFAOYSA-N 0.000 description 1
- UXLDFTUCNFDMOT-UHFFFAOYSA-N 2,3-dihydroxy-2-(2-methylbenzoyl)butanedioic acid Chemical compound CC1=CC=CC=C1C(=O)C(O)(C(O)C(O)=O)C(O)=O UXLDFTUCNFDMOT-UHFFFAOYSA-N 0.000 description 1
- AMPNBNGNPLXMOP-UHFFFAOYSA-N 2-(2,3-dimethylphenyl)acetic acid Chemical compound CC1=CC=CC(CC(O)=O)=C1C AMPNBNGNPLXMOP-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- XRHFZSYFAHNUCN-UHFFFAOYSA-N C(CCC)O.N1CCCCC1 Chemical compound C(CCC)O.N1CCCCC1 XRHFZSYFAHNUCN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 101100033673 Mus musculus Ren1 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZRTHDHYYZUCESV-UHFFFAOYSA-N acetic acid;1,2-xylene Chemical compound CC(O)=O.CC1=CC=CC=C1C ZRTHDHYYZUCESV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001733 carboxylic acid esters Chemical group 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZFLJBPPHKFQKJM-UHFFFAOYSA-N dinaphthalen-1-yl hydrogen phosphate Chemical compound C1=CC=C2C(OP(=O)(OC=3C4=CC=CC=C4C=CC=3)O)=CC=CC2=C1 ZFLJBPPHKFQKJM-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000009972 noncorrosive effect Effects 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- XYKIUTSFQGXHOW-UHFFFAOYSA-N propan-2-one;toluene Chemical compound CC(C)=O.CC1=CC=CC=C1 XYKIUTSFQGXHOW-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24291994A | 1994-05-16 | 1994-05-16 | |
US24291994 | 1994-05-16 | ||
US9504422 | 1995-04-10 | ||
PCT/US1995/004422 WO1995031436A1 (en) | 1994-05-16 | 1995-04-10 | PROCESS AND DIASTEREOMERIC SALTS USEFUL FOR THE OPTICAL RESOLUTION OF RACEMIC α-[4-(1,1-DIMETHYLETHYL)PHENYL]-4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINEBUTANOL AND DERIVATIVE COMPOUNDS |
Publications (3)
Publication Number | Publication Date |
---|---|
FI964566A0 FI964566A0 (fi) | 1996-11-14 |
FI964566A FI964566A (fi) | 1996-11-14 |
FI114095B true FI114095B (fi) | 2004-08-13 |
Family
ID=22916643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI964566A FI114095B (fi) | 1994-05-16 | 1996-11-14 | Menetelmä ja diastereomeerisia suoloja, jotka ovat käyttökelpoisia raseemisen 4-[4-[4-(hydroksidifenyylimetyyli)- 1-piperidinyyli]-1-hydroksibutyyli]-alfaalfa-dimetyylibentseenietikkahapon optisessa resoluutiossa |
Country Status (22)
Country | Link |
---|---|
US (3) | US20030078429A1 (zh) |
EP (1) | EP0759904B1 (zh) |
JP (1) | JPH10503752A (zh) |
KR (1) | KR100387459B1 (zh) |
CN (3) | CN1119330C (zh) |
AT (1) | ATE194328T1 (zh) |
AU (1) | AU689578B2 (zh) |
CA (1) | CA2189000C (zh) |
DE (1) | DE69517810T2 (zh) |
DK (1) | DK0759904T3 (zh) |
ES (1) | ES2149357T3 (zh) |
FI (1) | FI114095B (zh) |
GR (1) | GR3034444T3 (zh) |
HK (2) | HK1039485A1 (zh) |
IL (1) | IL113738A (zh) |
MX (1) | MX9605611A (zh) |
NO (1) | NO308031B1 (zh) |
NZ (1) | NZ284277A (zh) |
PT (1) | PT759904E (zh) |
TW (1) | TW424085B (zh) |
WO (1) | WO1995031436A1 (zh) |
ZA (1) | ZA953793B (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6242464B1 (en) | 1996-01-22 | 2001-06-05 | Chiroscience Limited | Single isomer methylphenidate and resolution process |
MX9805870A (zh) * | 1996-01-22 | 1999-01-31 | ||
US5925761A (en) * | 1997-02-04 | 1999-07-20 | Sepracor Inc. | Synthesis of terfenadine and derivatives |
DE10145223A1 (de) * | 2001-09-13 | 2003-04-03 | Basf Ag | Verfahren zur Herstellung von meso-Zeaxanthin |
ITMI20041568A1 (it) * | 2004-07-30 | 2004-10-30 | Dipharma Spa | "polimorfi di fexofenadina base" |
CA2647362C (en) | 2006-03-14 | 2014-10-14 | University Of Southern California | Mems device and method for delivery of therapeutic agents |
ES2425769T5 (es) | 2007-12-20 | 2017-07-28 | University Of Southern California | Aparato para la administración de agentes terapéuticos |
US8486278B2 (en) | 2008-05-08 | 2013-07-16 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
EP2898911A1 (en) | 2008-05-08 | 2015-07-29 | MiniPumps, LLC | Implantable pumps and cannulas therefor |
US9333297B2 (en) | 2008-05-08 | 2016-05-10 | Minipumps, Llc | Drug-delivery pump with intelligent control |
ES2509220T3 (es) * | 2009-01-16 | 2014-10-17 | Basf Se | Separación de una mezcla de enantiómeros de (R)- y (S)-3-amino-1-butanol |
EP2467797B1 (en) | 2009-08-18 | 2017-07-19 | MiniPumps, LLC | Electrolytic drug-delivery pump with adaptive control |
CN103497145B (zh) * | 2013-10-10 | 2016-01-27 | 南昌大学 | 一种光学纯多奈哌齐的制备工艺 |
AU2019347545B2 (en) * | 2018-09-28 | 2024-06-13 | Celltrion, Inc. | Novel method for preparing (-)-Cibenzoline succinate |
KR20220084103A (ko) * | 2019-10-17 | 2022-06-21 | 바이엘 악티엔게젤샤프트 | 부분입체이성질체 타르타르산 에스테르를 사용한 라세미체 분해에 의한 2-시아노에틸 (4s)-4-(4-시아노-2-메톡시페닐)-5-에톡시-2,8-디메틸-1,4-디히드로-1,6-나프티리딘-3-카르복실레이트의 제조 방법 |
MX2022004468A (es) * | 2019-10-17 | 2022-05-03 | Bayer Ag | Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxi-feni l)-5-hidroxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxilato de 2-cianoetilo por separacion de racematos por medio de ester de acido tartarico diastereoisomero. |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3452086A (en) * | 1966-04-29 | 1969-06-24 | Bristol Myers Co | Substituted tartranilic acid resolving agents |
IT951631B (it) * | 1971-03-18 | 1973-07-10 | Richardson Merrell Spa | Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi |
US3878217A (en) * | 1972-01-28 | 1975-04-15 | Richardson Merrell Inc | Alpha-aryl-4-substituted piperidinoalkanol derivatives |
FR2201108B1 (zh) * | 1972-09-25 | 1977-12-23 | Copier Henri | |
US4128663A (en) * | 1977-03-15 | 1978-12-05 | The Upjohn Company | Anilide derivatives as antidepressants |
US4285957A (en) * | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof |
US4254129A (en) * | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
EP0108817A1 (en) * | 1982-11-06 | 1984-05-23 | Kanegafuchi Chemical Industry Co., Ltd. | Stable composition of S-adenosyl-L-methionine and process for preparation thereof |
JPS59210086A (ja) * | 1983-05-13 | 1984-11-28 | Kyowa Hakko Kogyo Co Ltd | Dx―52―1類及びその塩類 |
JP2792046B2 (ja) * | 1987-10-09 | 1998-08-27 | 住友化学工業株式会社 | 光学活性なアミン−ホウ素系化合物、それを有効成分とする不斉還元剤ならびにそれを用いる光学活性化合物の製造方法 |
US4931557A (en) * | 1988-10-17 | 1990-06-05 | Eli Lilly And Company | Method of resolving cis 3-amino-4-(2-furyl)vinyl)-1-methoxycarbonylmethyl-azetidin-2-one and di-p-toluoyl-tartaric acid salts thereof |
US4968837A (en) * | 1989-07-28 | 1990-11-06 | Ethyl Corporation | Resolution of racemic mixtures |
-
1995
- 1995-04-10 KR KR1019960706571A patent/KR100387459B1/ko not_active IP Right Cessation
- 1995-04-10 JP JP7529641A patent/JPH10503752A/ja not_active Ceased
- 1995-04-10 ES ES95916294T patent/ES2149357T3/es not_active Expired - Lifetime
- 1995-04-10 DK DK95916294T patent/DK0759904T3/da active
- 1995-04-10 CN CN95193082A patent/CN1119330C/zh not_active Expired - Lifetime
- 1995-04-10 NZ NZ284277A patent/NZ284277A/en not_active IP Right Cessation
- 1995-04-10 DE DE69517810T patent/DE69517810T2/de not_active Expired - Lifetime
- 1995-04-10 CN CNB2005101075877A patent/CN100369897C/zh not_active Expired - Lifetime
- 1995-04-10 CN CNB001201409A patent/CN1229346C/zh not_active Expired - Lifetime
- 1995-04-10 AT AT95916294T patent/ATE194328T1/de active
- 1995-04-10 PT PT95916294T patent/PT759904E/pt unknown
- 1995-04-10 MX MX9605611A patent/MX9605611A/es unknown
- 1995-04-10 EP EP95916294A patent/EP0759904B1/en not_active Expired - Lifetime
- 1995-04-10 CA CA002189000A patent/CA2189000C/en not_active Expired - Lifetime
- 1995-04-10 WO PCT/US1995/004422 patent/WO1995031436A1/en active IP Right Grant
- 1995-04-10 AU AU22840/95A patent/AU689578B2/en not_active Expired
- 1995-05-10 ZA ZA953793A patent/ZA953793B/xx unknown
- 1995-05-11 TW TW084104669A patent/TW424085B/zh not_active IP Right Cessation
- 1995-05-15 IL IL11373895A patent/IL113738A/xx not_active IP Right Cessation
-
1996
- 1996-11-14 FI FI964566A patent/FI114095B/fi not_active IP Right Cessation
- 1996-11-15 NO NO964858A patent/NO308031B1/no not_active IP Right Cessation
-
2000
- 2000-09-20 GR GR20000402136T patent/GR3034444T3/el unknown
-
2001
- 2001-12-27 HK HK01109104A patent/HK1039485A1/xx not_active IP Right Cessation
-
2002
- 2002-07-10 US US10/192,444 patent/US20030078429A1/en not_active Abandoned
-
2004
- 2004-01-29 US US10/767,790 patent/US20040186137A1/en not_active Abandoned
-
2005
- 2005-09-15 US US11/227,246 patent/US20060014793A1/en not_active Abandoned
-
2006
- 2006-08-15 HK HK06109035.2A patent/HK1088603A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI114095B (fi) | Menetelmä ja diastereomeerisia suoloja, jotka ovat käyttökelpoisia raseemisen 4-[4-[4-(hydroksidifenyylimetyyli)- 1-piperidinyyli]-1-hydroksibutyyli]-alfaalfa-dimetyylibentseenietikkahapon optisessa resoluutiossa | |
Arrowsmith et al. | Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents | |
CA1184180A (fr) | Derives de (quinolyl-2, ou -3 ou -4)-1 (piperidyl ou pyrrolidinyl-2 ou -3)-2 ou -3 ethanone ou propanone, procedes pour leur preparation, et leur utilisation comme medicaments | |
FI57749C (fi) | Foerfarande foer framstaellning av analgetiska n-/1-(omega-fenylalkyl)-piperidyl-4/-n-(alfa-pyridyl)-karbonsyraamider och deras syraadditionssalter | |
KR880000180B1 (ko) | 디하이드로 피리딘의 제조방법 | |
KR19990081891A (ko) | 오,오'-비사로일 타르타르산에 의한 메틸페니데이트의 광학적분리방법 | |
AU698637B2 (en) | Crystallisation of levobupivacaine and analogues thereof | |
US6384227B2 (en) | Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents | |
US5153207A (en) | Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same | |
AU701221B2 (en) | Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents | |
US5965734A (en) | Processes and intermediates for preparing 2-substituted piperidine stereoisomers | |
FI95371C (fi) | Menetelmä ja välituotteet enantiomeerisesti puhtaiden polysubstituoitujen 1,4-dihydropyridiinien valmistamiseksi | |
JPH0517900B2 (zh) | ||
JP4083800B2 (ja) | 抗虚血性ヒドロキシルアミン誘導体および医薬組成物 | |
US5219867A (en) | Platelet aggregation inhibitory agents | |
EP0965591B1 (de) | Verfahren zur Herstellung von (S)-3-Methyl-1-(2-piperidino-phenyl)-1-butylamin | |
JP2717257B2 (ja) | 光学活性化合物の製造法 | |
HU220968B1 (hu) | Eljárás racém alfa-[4-(1,1-dimetil-etil)-fenil]4-[4-(hidroxi-difenil-metil)-1-piperidin]-butanolok és származékaik optikai elválasztására és a diasztereomer sók | |
KR800000852B1 (ko) | 4-(4-코로로페닐)-4-히드록시-N, N-디메틸-α, α-디페닐-1-피페리딘부탄 아미드 및 그의 부가염의 제조방법. | |
US5633383A (en) | Process for producing optically pure 1,4-dihydropyridines | |
HU207292B (en) | Process for producing pyrrolidine derivatives | |
JPH0778049B2 (ja) | 新規なアルキレンジアミン誘導体およびグルタミン酸遮断剤 | |
HU191585B (en) | Process for producing tetramethyl-proline-3-carboxamide derivatives and new cardiotherapeutic compositions containing them | |
DES0031249MA (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Transfer of assignment of patent |
Owner name: AVENTIS INC. Free format text: AVENTIS INC. |
|
PC | Transfer of assignment of patent |
Owner name: AVENTISUB II INC. Free format text: AVENTISUB II INC. |
|
MA | Patent expired |